Featured resident: Mediphage Bioceuticals

Mediphage Bioceuticals is a genetic medicine company that has developed the safest transgene delivery vector on the market, DNA ministrings (msDNA). msDNA has applications across a range of applications including DNA vaccines, iPSC, gene editing, gene therapy, and cell engineering.

msDNA’s non-immunogenic nature allows us to move us from single-dose gene therapy treatments to redosable, titratable “genetic medicine”. This represents true cures to genetic disease, not merely treatments, signalling a paradigm shift in the industry. DNA ministrings are safe and effective vectors for gene delivery. Their natural topology as stable linear covalently closed “strings” provides superior safety to other current tools for therapeutic DNA delivery and genetic manipulation. Furthermore, DNA ministrings can be manufactured through a scalable and inexpensive bacterial fermentation using a simple temperature shift, offering a significant advantage over competing technologies.

Area of focus: Therapeutics
Commencement date: February 24, 2017
Location: JLABS @ Toronto